DONATE

Nanobioengineering


About

The Nanobioengineering group is a truly multidisciplinary team composed by researchers coming from very diverse backgrounds working together in applying nanotechnology for the development of new biomedical systems and devices, mainly for diagnostic purposes, and integrated microfluidic Organ-on-Chip devices for the study of organ physiology, disease etiology, or drug screening.

The goal is to fabricate microsystems containing living cells that recapitulate tissue and organ level functions in vitro and new portable diagnosis devices that can be used as Point-of-Care systems.

The main research activities of the group include the engineering and biochemical functionalization of biomaterials integrated with microfluidics systems. The bioengineered microdevices are used to study cell responses to biomolecular compounds applied to Organ-on-Chip devices, or for the development of new lab-on-a-chip based biosensors.

The projects carried out by the group are focused on clinical and industrial problems and are related to three convergent research lines:

1. Biosensors and Lab-on-a-Chip devices for clinical diagnosis and monitoring
  • DNA sensors-arrays integrated in lab-on-a-chip for portable point of care diagnosis
  • Vascular implantable sensors for circular cancer biomarker detection.
  • Antibody-based sensors for pathogenic microorganisms’ detection and neurodegenerative early detection
  • Implantable physiological sensors-array for tissue in vivo hypoxia and ischemia monitoring.
  • 3D printing microfluidic technology.
  • Microfluidic chip using hydrodynamic forces for cell counting and sorting. Application for detection of circulating tumours cells (CTCs).
2. Nanotechnology applied to biomolecule interaction studies and micro/nano-environments for regenerative medicine applications
  • Development of bioengineered 2D and 3D micro/nanoenvironments with a topography and chemical composition controlled at the nanoscale for cell behavior studies (adhesion, proliferation, differentiation). Application to musculoskeletal system regeneration.
  • Biophysical description of cellular phenomena (adhesion, cell migration, differentiation) using micro/nanotechnologies, cell biology tools and soft matter physics.
  • Study of biological mechanisms at single molecule level.
  • Study of magnetite nanoparticles – Amyloid-Beta interaction in Alzheimer disease.
3. Microfluidic systems for biological studies and Organ-on-Chip devices
  • Microfluidic chip for blood/plasma filtering and anemia diseases characterization
  • Spleen-on-a-chip development.
  • Nanoporous-based systems for kidney-on–a-chip developments.
  • Engineering microfluidic platforms for neurobiological studies.
  • Development of 3D neuromuscular tissue models for soft robotics and clinical applications
  • Microfluidic system to monitor cancer therapy response. Tumor Cancer on a chip in vitro development.
  • Microfluidic vessel on-a-chip for screening drug delivery systems.

Staff

Projects

NATIONAL PROJECTSFINANCERPI
BASE3D (2019-2022)RIS3CAT Tecnologies EmergentsJosep Samitier
PREMED Desarrollo de un ensayo microfluídico funcional en células para el tratamiento personalizado contra el cáncer (2019-2022)MICIU: Retos investigaciónJoan Montero
Sistema microfisiológico para mimetizar las barreras hemato-sistema nervioso central: aplicación a la esclerosis lateral amiotrófica (2019-2022)MICIU: Retos investigaciónAnna Lagunas
BATMAN Nanopartículas biomiméticas para el tratamiento dirigido del neuroblastoma pediátrico (2021-2023)MICIU, Retos investigación: Proyectos I+D. Aranzazu Villasante
Neuroblastoma en un chip para investigar la resistencia a fármacos y el uso de nanopartículas terapéuticas (2018-2022)Asociación Española contra el Cáncer (AECC)Aranzazu Villasante
Evaluación Funcional de respuesta celular a la quimioterapia neoadyuvante en Sarcoma de tejido blando (2021-2024)Fundación Mari Paz Jiménez Casado (FMPJC), Beca Trienal FMPJC Investigación SarcomasJoan Montero
INTERNATIONAL PROJECTSFINANCERPI
ASCTN-Training Training on Advanced Stem Cell Technologies in Neurology (2018-2022)European Comission Marie Curie ITNJosep Samitier
EVIDENCE Erythrocytes properties and viability in dependence of flow and extra-cellular environment (2020-2023)European Comission Marie Curie ITNJosep Samitier
PANDORA Pandemics Outbreaks Rationalized: towards a universal therapy to eliminate intracellular pathogens (2020-2025)European Commission, ERC – StG Josep Samitier
BEST Postdoctoral Programme in Bioengineering Excellence Scientific Training (2017-2022)European Commission, COFUND – Marie Sklodowska-Curie Co-funding of regional, national and international programmes Josep Samitier
SCIFI From Scientists to Innovators for Industry (2022-2024)EIT Health, EITHealth BP2022 Education Josep Samitier
PRIVATELY-FUNDED PROJECTSFINANCERPI
Descubrimiento de nuevos marcadores terapéuticos en neuroblastoma mediante la generación de modelos basados en técnicas de ingeniería de cáncer (2021-2023)Associació pacients NENJosep Samitier /Aranzazu Villasante
Understanding and measuring mechanical tumor properties to improve cancer diagnosis, treatment, and survival: Application to liquid biòpsies (2017-2022)Obra Social La CaixaJosep Samitier
BCNatal Artificial Placenta Project (2021-2022)Obra Social La CaixaMaria José López
Descubrimiento de nuevos marcadores terapéuticos en neuroblastoma mediante la generación de modelos basados en técnicas de ingeniería de cáncer (2021-2023)Associació pacients NENAranzazu Villasante
FINISHED PROJECTSFINANCERPI
Personalizing pediatric cancer treatment with kinome analyses, cell-based funcional assays and microfluidics (2017-2021)CELLEXJosep Samitier / Joan Montero
ISCHEMSURG Miniaturized electrochemical sensor for monitoring of free flap ischemia in post-surgery (2019-2021)AGAURJosep Samitier
Joint Programme – Healthy Ageing (2016)Obra Social “La Caixa”Josep Samitier
PLANTOID Innovative Robotic Artefacts Inspired by Plant Roots for Soil MonitoringICTJosep Samitier
Universal diagnostic platforms based on oligonucleotide cofidied nanoparticles and DNA microarray sensor devicesMINECO, I+D-Investigación fundamental no orientadaJosep Samitier
ELECTRA-G (2014-2016)Conveni GENOMICA S.A.U.Josep Samitier
Desarrollo de una nueva tecnología lab-on-a-chip para la detección y cuantificación de secuencias de ADN/ARN (2014-2016)Conveni GENOMICA S.A.U.Josep Samitier
BIOBOT Engineered biological soft robots based on neuro-muscular junction control (2015-2018)MINECO, Proyectos EXPLORA Ciencia / Tecnología 2015Josep Samitier
Advancecat Acceleradora pel desenvolupament de teràpies avançades
ACCIÓ / Smart Specialization funds (RIS3)Josep Samitier
MINDS Plataforma MIcrofluídica 3D de cultivo Neuronal compartimentada para el estuDio de enfermedades neurológicaS (2016-2018)MINECO, Proyectos I+D ExcelenciaJosep Samitier
nanoET-leukemia Nanoconductance of electron transfer proteins of the respiratory chain. Direct measurementat the single molecular level and therapeutic regulation in cancer stem cells (2015-2018)MINECO, Proyectos RETOS 2015 / CIBERAnna Lagunas / Marina Giannotti
Desenvolupar un sistema d’assistència robòtica per medicina i cirurgia fetal (2016-2019)CELLEXJosep Samitier
Monitoring neurocognitive deficits in Alzheimer’s and Parkinson’s diseases using saliva or blood-derived biomarkers and a multiplexed approach (2016-2018)Obra Social “La Caixa”Josep Samitier
ISCHEMSURG Miniaturized electrochemical sensor for monitoring of free flap ischemia in post-surgery (2019-2020)CaixaImpulseMonica Mir
Personalizing Melanoma Treatment Using Dynamic BH3 Profiling (2018-2020)Dana-Farber Cancer InstitutJoan Montero
NANOVAX Nanovacunas diseñadas para inmunoterapia antitumoral (2016-2020)EuroNanoMed (ERA-Net)Josep Samitier
Understanding and measuring mechanical tumor properties to improve cancer diagnosis, treatment, and survival: Application to liquid biopsies (2017-2020)Obra Social “La Caixa”Josep Samitier
Personalizing pediatric cancer treatment (2018-2020)Fundación FEROJoan Montero

Publications

Equipment

Nanofabrication and nanomanipulation

  • 3D Printing system for microfluidic devices
  • Graphtech

Characterization

  • Potentiostates
  • Optical Waveguide Lightmode Spectroscope (OWLS)
  • Atomic Force Microscope (AFM)
  • Optical Microscopes (white light/epifluorescence)
  • Electrical Impedance spectroscopy (EIS)
  • Multi-frequency Lock-in Amplifier
  • Sub-femtoamp Remote SourceMeter Instrument

Molecular/cell biology

  • Biological safety cabinet (class II)
  • Microwell plate readers
  • Protein and DNA electrophoresis systems
  • Microincubator Okolab
  • Nanodrop spectrophotometer
  • CO2 incubator for cells: Galaxy® 48 S, 48 L, 230 V/50/60 Hz, standard
  • Cell culture cabin: Bioii-Advance 3

Microfluidics

  • High precision syringe pumps
  • Peristaltic pumps

Collaborations

  • Prof. Fernando Albericio
    Institut de Recerca Biomédica (IRB), Barcelona, Spain
  • Dr. José Antonio Andrades
    Universidad de Málaga, Spain
  • Prof. Ezequiel Pérez
    Inestrosa Centro Andaluz de Nanomedicina y Biotecnología (BIONAND), Málaga, Spain
  • Prof. Joan Bausells
    Centro Nacional de Microelectrónica (CNM-CSIC), Barcelona
  • Prof. Albert van den Berg
    University of Twente, The Netherlands
  • Prof. Andre Bernard
    Institut für Mikro- und Nanotechnologie (MNT-NTB), Buchs, Switzerland
  • Prof. H. Börner
    Max Planck Institute of Colloids and Interfaces, Golm, Germany
  • Prof. Josep Maria Canals
    University of Barcelona, Spain
  • Dr. Matthew Dalby
    University of Glasgow, UK
  • Prof. Paolo Dario
    Scuola Superiore Sant’Anna (SSSA), Pontedera, Italy
  • Prof. Ramón Eritja
    Institut de Recerca Biomédica (IRB), Barcelona, Spain
  • Prof. E. Faszewski
    Wheelock College, Boston, USA
  • Prof. G. Fuhr
    FhG Biomedicine, St. Ingbert, Germany
  • Dr. Juan C. Izpisúa
    Salk Institute for Biological Studies, La Jolla, California
  • Dr. Nicole Jaffrezic
    Université Claude Bernard Lyon 1, France
  • Dr. Graham Johnson
    Uniscan Instruments Ltd, Buxton, UK
  • Dr. Mª Pilar Marco
    Institute of Chemical and Environmental Research, Barcelona
  • Prof. Jean-Louis Marty
    Université de Perpignan Via Domitia, France
  • Prof. Barbara Mazzolai
    IIT Center for Micro-BioRobotics (CMBR), Pontedera, Italy
  • Dr. Edith Pajot
    Biology of Olfaction and Biosensors group (BOB) at INRA, Jouy-en-Josas, France
  • Dr. M. Lluïssa Pérez
    Dept. Farmacología, University of Barcelona, Spain
  • Dr. Hernando del Portillo
    Centro de Investigación en Salud Internacional de Barcelona (CRESIB), Barcelona, Spain
  • Dr. Jaume Reventós
    Hospital Vall d’Hebrón, Barcelona, Spain
  • Prof. L. Reggiani
    Nanotechnology Laboratory, INFM, Lecce, Italy
  • Prof. Daniel Riveline
    Laboratory of Cell Physics ISIS/IGBMC, Strasbourg
  • Prof. M. Sampietro
    Politecnico di Milano, Italy
  • Prof. Molly M. Stevens
    Imperial College, London, UK
  • Dr. Christophe Vieu
    Laboratoire d’analyse et d’architectures des systèmes (LAAS-CNRS), Toulouse, France
  • Prof. Pau Gorostiza
    IBEC
  • Prof. Irene Díaz Moreno
    3IIQ-cicCartuja, Universidad de Sevilla-CSIC, Spain
  • Prof. Miguel A. de la Rosa
    3IIQ-cicCartuja, Universidad de Sevilla-CSIC, Spain
  • Dr. María del Mar Mañú Pereira
    Josep Carreras Leukaemia Research Institute, Barcelona, Spain
  • Dr. Joan Lluis Vives
    Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Industry partners:

  • Biokit S.A. (Werfen group); Genomica S.A.U. (Zeltia group); Tallers Fiestas S.L.; Enantia S.L.; Microfluidic ChipShop GmbH; Minifab; Microliquid

News

Josep Samitier, director of the Institute for Bioengineering of Catalonia and president of the Catalan Association of Research Entities (ACER), assesses how science and technology can be affected by the fact that 53 million euros, that had to be invested in research, have been redirected to the healthcare sector, due to the coronavirus outbreak.

Josep Samitier talks about how the redistribution of funds will affect research

Josep Samitier, director of the Institute for Bioengineering of Catalonia and president of the Catalan Association of Research Entities (ACER), assesses how science and technology can be affected by the fact that 53 million euros, that had to be invested in research, have been redirected to the healthcare sector, due to the coronavirus outbreak.

The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases. When in early 2020, more than 200 scientists gathered in La Pedrera in Barcelona to discuss the present and future of bioengineering, no one imagined that the world would experience the first pandemic of the 21st century and that science would take on more importance than ever.

IBEC receives a visit from the Mayor of Barcelona interested in our research against Covid19

The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases. When in early 2020, more than 200 scientists gathered in La Pedrera in Barcelona to discuss the present and future of bioengineering, no one imagined that the world would experience the first pandemic of the 21st century and that science would take on more importance than ever.

On May 13, the new National Agreement for a Knowledge-based Society was presented at the appearance of the President of the Catalan Government and the Minister for Business and Knowledge. This pact proposes the public policies that would have to be carried out so that Catalonia to becomes a leader in research and innovation at the international level.

IBEC’s director contributes to the new National Agreement for a Knowledge-based Society

On May 13, the new National Agreement for a Knowledge-based Society was presented at the appearance of the President of the Catalan Government and the Minister for Business and Knowledge. This pact proposes the public policies that would have to be carried out so that Catalonia to becomes a leader in research and innovation at the international level.

IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments. Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.

Bioengineering contributes to new advances against childhood cancer

IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments. Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.

The Institute for Bioengineering of Catalonia (IBEC) will contribute its extensive experience in 3D printing and bioprinting to the BASE 3D community, an entity that brings together research centers and companies from all over Catalonia with the aim of promoting R+D+i in the field of printing 3D. The groups led by Josep Samitier, Elisabeth Engel, Núria Montserrat and Javier Ramón at IBEC are joining the BASE3D project.

IBEC joins the BASE3D community to contribute to the future of 3D printing

The Institute for Bioengineering of Catalonia (IBEC) will contribute its extensive experience in 3D printing and bioprinting to the BASE 3D community, an entity that brings together research centers and companies from all over Catalonia with the aim of promoting R+D+i in the field of printing 3D. The groups led by Josep Samitier, Elisabeth Engel, Núria Montserrat and Javier Ramón at IBEC are joining the BASE3D project.

Experts at Institute for Bioengineering of Catalonia (IBEC) led by Josep Samitier, the Director of the Institute, have contributed to an international project supported by the European Union to study red blood cells under realistic physiological conditions.

IBEC researchers contribute to make experiments on red blood cells more realistic

Experts at Institute for Bioengineering of Catalonia (IBEC) led by Josep Samitier, the Director of the Institute, have contributed to an international project supported by the European Union to study red blood cells under realistic physiological conditions.

The conference organised by the Institute for Bioengineering of Catalonia (IBEC) and the European Molecular Biology Laboratory (EMBL) brought together a total of 200 international experts in the field of bioengineering at La Pedrera building in Barcelona.

EMBL-IBEC Winter Conference 2020

The conference organised by the Institute for Bioengineering of Catalonia (IBEC) and the European Molecular Biology Laboratory (EMBL) brought together a total of 200 international experts in the field of bioengineering at La Pedrera building in Barcelona.

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future. Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future. Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

Last 9-11th of October took place in Beijing the workshop on “Engineering and Manufacture of Living Systems”. The aim of the workshop was to bring together multi-disciplinary researchers to review the latest advances and discuss the future directions in the design and manufacture of engineered living systems, and their integration amongst the researchers gathered at this international workshop. The major topics discussed during the workshop were: to consider issues related to translation of engineered living systems from the laboratory to the clinic and to industry, review enabling and emerging techniques for using pluripotent cells from various sources such as cell spheroids, organoids and organs-on-a-chip, discuss the ethical, societal and regulatory issues associated with the development and manufacture of engineered living systems and envision future research, development and synergies at the integration and interface of biomanufacturing and engineering living systems amongst others. The meeting was organised by Tsinghua University and the Massachusetts Institute of Technology.

Josep Samitier and Núria Montserrat at the “Engineering and Manufacture of Living Systems” workshop in China

Last 9-11th of October took place in Beijing the workshop on “Engineering and Manufacture of Living Systems”. The aim of the workshop was to bring together multi-disciplinary researchers to review the latest advances and discuss the future directions in the design and manufacture of engineered living systems, and their integration amongst the researchers gathered at this international workshop. The major topics discussed during the workshop were: to consider issues related to translation of engineered living systems from the laboratory to the clinic and to industry, review enabling and emerging techniques for using pluripotent cells from various sources such as cell spheroids, organoids and organs-on-a-chip, discuss the ethical, societal and regulatory issues associated with the development and manufacture of engineered living systems and envision future research, development and synergies at the integration and interface of biomanufacturing and engineering living systems amongst others. The meeting was organised by Tsinghua University and the Massachusetts Institute of Technology.

The European Molecular Biology Laboratory (EMBL) and the Institute for Bioengineering of Catalonia (IBEC) aim to strengthen future collaboration between the two research institutions. With this purpose, IBEC Director’s Josep Samitier and Edith Heard, Director of EMBL, have signed a 5-year agreement at EMBL Barcelona headquarters. This collaboration is the beginning of a working framework for activities between EMBL and IBEC which support strategic long-term scientific and general collaboration in areas of mutual interest. Some of the proposed join projects are a postdoc EMBL-IBEC program and a series of EMBL-IBEC seminars. Moreover, it is also planned to reinforce visitors’ exchange whereby scientific personnel affiliated to EMBL or IBEC will have the possibility to visit the facilities of the other institution in order to study research developments and techniques and to foster interdisciplinary collaborations.

IBEC and EMBL join forces

The European Molecular Biology Laboratory (EMBL) and the Institute for Bioengineering of Catalonia (IBEC) aim to strengthen future collaboration between the two research institutions. With this purpose, IBEC Director’s Josep Samitier and Edith Heard, Director of EMBL, have signed a 5-year agreement at EMBL Barcelona headquarters. This collaboration is the beginning of a working framework for activities between EMBL and IBEC which support strategic long-term scientific and general collaboration in areas of mutual interest. Some of the proposed join projects are a postdoc EMBL-IBEC program and a series of EMBL-IBEC seminars. Moreover, it is also planned to reinforce visitors’ exchange whereby scientific personnel affiliated to EMBL or IBEC will have the possibility to visit the facilities of the other institution in order to study research developments and techniques and to foster interdisciplinary collaborations.

1 4 5 6 7 8

Jobs